MAPT and Alzheimer disease: Therefore, we sought corroborative evidence of regional distributions of feature attribution in our study and validate them with previous classical studies discussing the clinical use of MRI and mapping the evolution of regional atrophy in AD (Frisoni et al. 2010; Scahill et al. 2002), and from other studies more specifically probing regional amyloid and tau pathology distribution patterns (Aksman et al. 2023; Farrar et al. 2019; Grothe et al. 2017; Hansson et al. 2017; Hoenig et al. 2018; Storandt et al. 2009).